Alector

Alector CapEx/OCF

The CapEx to Operating Cash Flow Ratio of Alector (ALEC) as of Nov 5, 2026 is -0.02 %. In the previous year, CapEx to Operating Cash Flow Ratio was -0.55 % — a change of -95.92% (higher).

CapEx/OCF

-0.02 %

YoY

-95.92%

Last updated:

CapEx to Operating Cash Flow Ratio of Alector is 2025 -0.02 % . CapEx to Operating Cash Flow Ratio of Alector was 2024 -0.55 % . It decreases by -95.92% higher compared to the previous year.

The Alector CapEx/OCF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

CapEx/OCF
Date
CapEx/OCF
Jan 1, 2018
1.48 USD
Jan 1, 2019
-15.37 USD
Jan 1, 2020
-3.02 USD
Jan 1, 2021
1.09 USD
Jan 1, 2022
-20.25 USD
Jan 1, 2023
-1.29 USD
Jan 1, 2024
-0.55 USD
Jan 1, 2025
-0.02 USD
The Alector CapEx/OCF history
YEARCapEx/OCFYoY
-0.02 %-95.92%
-0.55 %-57.78%
-1.29 %-93.62%
-20.25 %-1,962.09%
1.09 %-136.04%
-3.02 %-80.37%
-15.37 %-1,139.97%
1.48 %-132.79%
-4.51 %-73.97%
-17.32 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Alector Stock analysis

What does Alector do? Alector Inc. is a biotechnology company that was founded in 2013. The company's core competency is developing targeted therapies for previously incurable neurodegenerative diseases. The company is based in South San Francisco, California, and was founded by a group of renowned scientists. The founders aimed to develop innovative approaches to treat Alzheimer's and other neurodegenerative diseases by drawing inspiration from the processes of the immune system. Alector has a unique business model based on identifying antibodies to combat neurodegeneration. The company works closely with academics, pharmaceutical partners, and clinicians to develop drug candidates targeting various aspects of these serious diseases. Alector has developed a platform technology called the "Lead-Selective Integrated Discovery Platform" (LSP) that sets it apart. This platform is capable of identifying specific antibodies that can help inhibit disease mechanisms in neurodegenerative diseases. Alector has several products in various stages of development. A promising drug, AL001, is currently in Phase 1b/2a of clinical development for the treatment of Frontotemporal Dementia (FTD) and Amyotrophic Lateral Sclerosis (ALS). The drug aims to prevent overactivation of the immune system in the brain, which can contribute to disease symptoms. The company is also working on another drug, AL002, targeting Alzheimer's disease. It is still in preclinical development. Alector has also entered into a partnership with AbbVie Inc. (NYSE: ABBV) to develop antibody-based therapies for Alzheimer's disease and other neurological disorders. In addition to developing drug candidates, Alector also collaborates with other companies to make its technology platform accessible to other industries. In 2019, the company signed an agreement with GlaxoSmithKline plc (NYSE: GSK) granting GlaxoSmithKline access to the LSP platform. In summary, Alector Inc. is a leading biotechnology company specializing in the development of antibody-based therapies for neurodegenerative diseases. With innovative technology platforms and partnerships with other companies, Alector aims to create new treatment options for incurable diseases such as Alzheimer's and ALS. Alector is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Alector stock

CapEx to Operating Cash Flow Ratio of Alector is -0.02 % in 2025.

CapEx to Operating Cash Flow Ratio of Alector changed from -0.55 % to -0.02 %, representing a -95.92% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of CapEx to Operating Cash Flow Ratio Alector since 2006 – with annual values, charts, and detailed analysis.

The CapEx/OCF ratio shows what percentage of operating cash flow is reinvested in capital assets. Lower ratios indicate more free cash available for shareholders.

A 'good' varies by industry and company stage. On Eulerpool, you can compare CapEx to Operating Cash Flow Ratio's Alector with sector peers and the industry average to assess whether it is attractive.

To evaluate CapEx to Operating Cash Flow Ratio's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for CapEx to Operating Cash Flow Ratio.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Alector

All Key Metrics — Alector